Together with the observations that Ad‐NR2F6‐injected mice exhibited more hepatic TG contents, these findings suggest that upregulation of NR2F6 represents a common feature of obesity‐related dyslipidemia and might be causally linked to the pathogenesis of NAFLD. Here, NR2F6 is linked to metabolic syndrome.